Therapeutic Asset Ratings

8,399 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Adv/Hsv-Tk Glioblastoma	The Methodist Hospital Research Institute	P1/2	CCC (51)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Refractory Malignant Neoplasm	NKGen Biotech, Inc.	P1/2	CCC (51)
Amxt1501 Carcinoma	Aminex Therapeutics, Inc.	P1/2	CCC (51)
Azacitidine Myelofibrosis	M.D. Anderson Cancer Center	P1/2	CCC (51)
Calcium folinate pentahydrate Anal Cancer	Oncolytics Biotech	P1/2	CCC (51)
Calcium folinate pentahydrate Bladder Cancer	Arcus Biosciences, Inc.	P1/2	CCC (51)
Calcium folinate pentahydrate Urothelial Carcinoma	Memorial Sloan Kettering Cancer Center	P1/2	CCC (51)
Carboplatin Advanced or Metastatic Solid Tumors	NextCure, Inc.	P1/2	CCC (51)
cc-122 Non-Hodgkin Lymphoma	Bristol-Myers Squibb	P1/2	CCC (51)
cd19-ucart Lymphoma	University Hospital Tuebingen	P1/2	CCC (51)
CIS-DIAMMINEDICHLOROPLATINUM II Advanced or Metastatic Solid Tumors	Merck Sharp & Dohme LLC	P1/2	CCC (51)
Cladribine Mixed Phenotype Acute Leukemia	University of Washington	P1/2	CCC (51)
Cyclophosphamide Liver Metastases	VA Ann Arbor Healthcare System	P1/2	CCC (51)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301) Ductal Breast Carcinoma In Situ	Integro Theranostics	P1/2	CCC (51)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301) Invasive Ductal Breast Carcinoma	Integro Theranostics	P1/2	CCC (51)
Decitabine Metastatic Melanoma	Roswell Park Cancer Institute	P1/2	CCC (51)
DEXAMETHASONE Hematopoietic And Lymphoid Cell Neoplasm	Therapeutic Advances in Childhood Leukemia Consortium	P1/2	CCC (51)
Dostarlimab Cancer	iTeos Belgium SA	P1/2	CCC (51)
Durvalumab Urinary Bladder Carcinoma	M.D. Anderson Cancer Center	P1/2	CCC (51)
Durvalumab Colorectal Neoplasm	University of Iowa	P1/2	CCC (51)
e7386 Colorectal Neoplasm	Eisai Inc.	P1/2	CCC (51)
Eflornithine Advanced Cancer	Aminex Therapeutics, Inc.	P1/2	CCC (51)
Enitociclib NHL	National Cancer Institute (NCI)	P1/2	CCC (51)
Entinostat Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (51)
Enzalutamide Urinary Bladder Carcinoma	Cancer Research UK	P1/2	CCC (51)

Showing 701 to 725 of 8,399 assets

PreviousPage 29 of 336Next